Ingram WM, Weston C, Dar Lu W, … Larson S. Factors Affecting Electroconvulsive Therapy Ictal Outcomes: Duration and Postictal Suppression. AMIA Jt Summits Transl Sci Proc. 2019 May 6:672-79.
Katsanis SH, Huang E, Young A, Grant V, Warner E, Larson S, Wagner JK. Caring for trafficked and unidentified patients in the EHR shadows: Shining a light by sharing the data. PLOS ONE 2019 14(3):e0213766.
McTigue KM, Hartelius EJ, … Larson SL, et al. Using a deliberative forum for engaging health system and health plan leaders to prioritize research topics. European Journal for Person Centered Healthcare. 2018; 6(2):228-36.
White papers and reports
Larson S; Padron N; Mason J; Bogaczyk T. Supervised Consumption Facilities – Review of the Evidence. December 2017.
CPHR produced a scientific review of safe injection sites as a means to help combat the opioid epidemic. The study was produced by CPHR at the request of The Office of the Health Commissioner, Philadelphia Department of Public Health. Supervised consumption facilities, also known as safe drug injection sites or comprehensive user engagement sites, are medical interventions in which essential services are provided to reduce substance use, the harms associated with substance abuse, and fatal overdoses.
In popular media
Robinson P, Onyekere C, Padron N. Know Your Community to Improve Population Health. Hospitals & Health Networks. March 2, 2017.
Chen AF, Padrón NA, Becker CM. The Social Determinants of Health. Healthcare Transformation. 2017;2(2):43-51.
Padron N. The Hard Truth Behind Philly Health Statistics. Philadelphia magazine. May 6, 2017.
Larson, S. With suicide on the rise, it should now be viewed as a population health problem. Main Line Health Well Ahead blog. July 10, 2018.
Larson S, Padron N, Bogaczyk T, Mason J. Supervised consumption facilities — a review of the evidence (PDF). Poster presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 conference. May 2018; Baltimore, MD.
Larson S, Padron N. The case for harm reduction in Philadelphia. Poster presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 conference. May 2018; Baltimore, MD.
Larson S. Factors associated with secondary non-adherence to oral hypoglycemic among patients with type 2 diabetes (PDF). American Diabetes Association Scientific Sessions. June 2018; Orlando, FL.